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1. Introduction {#sec001}
===============

Neonatal hypoxic-ischemic brain damage (HIBD) is a severe disease that can cause irreversible neurological sequelae, such as cerebral palsy, mental deficiency, memory impairment and learning disabilities, and is often characterized by permanent neurological deficits \[[@pone.0228825.ref001], [@pone.0228825.ref002]\]. However, in some HIBD patients who receive early diagnosis and hypothermic treatments, still persist serious neurological sequelae. Currently, there is no effective clinical treatment for neurological sequelae induced by HIBD \[[@pone.0228825.ref003]--[@pone.0228825.ref005]\]. Thus, effective therapeutic agents which inhibit damage cascades activated after HIBD should be identified.

MicroRNAs are some small noncoding RNAs that regulate gene expression and suppression through several mechanisms. Recently microRNAs have been identified as critical mediators of neuroinflammation and neurodegeneration in HIBD \[[@pone.0228825.ref006], [@pone.0228825.ref007]\]. Precious reports have demonstrated that miR-30b is upregulated during HIBD and is involved in the regulation of cellular apoptosis after injury \[[@pone.0228825.ref008]\]. MicroRNA‐9 (miR-9) is highly expressed in the brain and has been implicated in the regulation of neurogenesis and proliferation as well as axonal development and neuronal migration \[[@pone.0228825.ref009]--[@pone.0228825.ref013]\]. As a result, miR-9 have unique advantages as targeted molecules in HIBD diagnosis and treatment. However, little attention been paid to the role of miR-9 in brain damage in infants caused by hypoxia.

Ferulic acid (FA) is a widely distributed constituent of plants which has been used for treating cerebrovascular diseases and cerebral ischemia by protecting neurons from degeneration and regulating inflammatory activity \[[@pone.0228825.ref014]--[@pone.0228825.ref016]\]. However, it is unknown whether the administration of FA has a neuroprotective effect on HIBD. Furthermore, the potential mechanisms remain unclear. Acetylcholinesterase (AchE), postsynaptic density protein-95 (PSD-95) involve in the progression of the transmission of nerve impulses,to evaluate the neuroprotective effect of FA, we currently examine the expression of AchE and PSD-95. In conclusion, we aimed to explore neuroprotective effect of FA on HIBD rats and further characterize the neuroprotective effect of FA on learning and memory ability, possibly via the downregulation of miR-9 following hypoxic-ischemic injury.

2. Methods and materials {#sec002}
========================

2.1. Preparation of SF and LNA-miR-9 {#sec003}
------------------------------------

Sodium ferulic (SF, the sodium salt form of FA, purity \>99.9%) was purchased from Dalian Meilunbio Biotechnology Co., Ltd. (CAS Registry Number: 24276-84-4, China), dissolved in 0.9% saline solution to a final concentration of 7 mg/ml, and subsequently stored at 4°C.

The sequence of LNA-miR-9 is 5\'-tcatacaGCtAgAtaACcaAaGa-3\', with the uppercase letters representing the sites of locked nucleic acid modifications \[[@pone.0228825.ref017]\]. LNA-miR-9 was synthesized by Sangon Biotech Co., Ltd. (Shanghai, China), dissolved in 0.01M PBS to a final concentration of 200 μM and stored at -20°C.

2.2. Cell culture and HI model establishment {#sec004}
--------------------------------------------

PC12 cells (obtained from ATCC and provided by the Laboratory of Biochemistry and Molecular Biology, Southwest Medical University) were maintained in RPMI-1640 medium (Hyclone, USA) containing 10% equine serum (Solarbio, China), 5% fetal bovine serum (Solarbio, China) at 5% CO~2~ and 37°C. Fresh medium was supplied every 48 h. The PC12 cells were divided into four groups: Control group, HI group, HI+SF group and HI+LNA group. In Control group, the PC12 cells were maintained in complete medium all the experiment time. To induce hypoxic-ischemic injury, cultured PC12 cells were serum-starved in RPMI-1640 medium supplemented with 1% equine serum and 1% fetal bovine serum and placed at 37°C in a humidified three-gas incubator (2% O~2~, 93% N~2~, and 5% CO~2~; NUAER) for 2 h \[[@pone.0228825.ref018]\]. All experiments were repeated at least three times.

2.3. Animals and HIBD model establishment {#sec005}
-----------------------------------------

One hundred and sixty-eight seven-day-old Sprague-Dawley (SD) rats, half male and half female, were provided by the Animal Department of Southwest Medical University (license number: SYXK (Sichuan) 2018--065, LuZhou City, China) and maintained under SPF conditions. The rats were divided into six groups randomly and treated in the following cohorts: In HIBD group, HIBD+SF group, HIBD+LNA group and HIBD+PBS group, the HIBD model was established by the classic method of Rice-Vannucci \[[@pone.0228825.ref019], [@pone.0228825.ref020]\]. In Sham group, the vagus nerve was separated but not ligated, and the pups were placed in a similar container but exposed to normal room air. In Control group, the pups maintained under normal conditions routinely without surgery.

All animal experiments were performed under the protocol approved by the Animal Research Committee of Southwest medical university in accordance with the "Health Guide for the Care and Use of Laboratory Animals" which approved by Sichuan Experimental Animal Management Committee (Protocol Number: 202089). All surgery was performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering.

2.4. Drug treatment {#sec006}
-------------------

Considering that the robust neuroprotective effects of SF (0.5 μg/ml) and LNA-miR-9 (50μM/ml) were observed *in vitro* experiment, we decided to use those concentration in the following *in vitro* studies. After HI model established, in HI+SF group and HI+LNA group, the PC12 cells were treated immediately with SF or LNA-miR-9 for 24 h.

14 days after the HIBD model established, the rats in HIBD+SF group intraperitoneally injected with 50 mg/kg SF one time per day for 5 days and the drug concentration is calculated by the Animal equivalent dose calculation based on body surface area. The rats in HIBD+LNA group received a terminal intraperitoneal injection of sodium pentobarbital, 2 μl (400 μM) of LNA-miR-9 was stereotaxically microinjected into the lateral ventricle (1.0 mm posterior to bregma, -0.8 mm from the midline, and -3.5 mm deep from the dura) within 15 min. The rats in HIBD+PBS group received a terminal intraperitoneal injection of sodium pentobarbital, 2 μl of 0.01M PBS was stereotaxically microinjected into the lateral ventricle within 15min. LNA-miR-9 and PBS treatment was only administered for one day.

2.5. RNA, miRNA and protein isolation {#sec007}
-------------------------------------

Cell pellets were taken at 24 hours after drug treatment; the rats were killed at 26 days old and the hippocampus were dissected on ice, snap-frozen in liquid nitrogen immediately. RNA and miRNA were isolated from the same cell pellet and hippocampus tissue using miRcute-miRNA Extraction and Isolation kit (TIANGEN, china) following the manufacturer's protocol. Proteins were isolated from another cell pellet and hippocampus tissue by using RIPA buffer (high) (Solarbio). RNA quality was checked on a denaturing RNA Ethidium bromide (EB) gel (1% agarose, 110 V, 30 min). After proteins were isolated already, the protein content was determined by using BCA Protein Assay Kit (Solarbio).

2.6. Real-time PCR {#sec008}
------------------

cDNA synthesis from mRNA was done with a ReverTra Ace qPCR RT Master Mix Kit (FSQ-201, TOYOBO, Japan) according to the manufacturers' protocols (800ng total RNA per reaction). cDNA synthesis from miRNA was performed with a miRcute Plus miRNA First-Strand cDNA Kit (KR-211, TIANGEN) according to the manufacturer's instructions (1μg total RNA).

Real-time qPCR was performed with a SYBR^®^ Green Realtime PCR Master Kit (TOYOBO) and miRcute Plus miRNA qPCR Kit (SYBR Green, TIANGEN) in a qTOWER^3^G device (Analytikjena, Germany). The specific PCR primers use for the detection of AchE, PSD-95 and β-actin were designed according to the NCBI sequence and synthesized by Sangon Biotech Co., Ltd. The sequences of the primers were as follows ([Table 1](#pone.0228825.t001){ref-type="table"}):
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###### Primer sequence.

![](pone.0228825.t001){#pone.0228825.t001g}

  Gene      Forward                       Reverse
  --------- ----------------------------- ----------------------------------------
  AchE      `ACTGAACTACACCGTGGAGGAGAG`    `TTCAGGTTCAGGCTCACGTATTGC`
  PSD-95    `CAATGAAGTCAGAGCCCCCTA`       `CCTGCAACTCATATCCTGGGG`
  β-actin   `CCCATCTATGAGGGTTACGC`        `TTTAATGTCACGCACGATTTC`
  miR-9     `TCTTTGGTTATCTAGCTGTATGA`     Downstream primer provided by the kit.
  U6        `GCTTCGGCAGCACATATACTAAAAT`   Downstream primer provided by the kit.

2.7. Western blot {#sec009}
-----------------

Western blotting was performed as described previously \[[@pone.0228825.ref021]\]. 10μg of protein was loaded on 10% SDS-PAGE gel followed by transfer to PVDF membranes (Millipore, USA). Blots were blocked with 5% skim milk (5g milk powder dissolved in 100ml TBS-T) for 1 h at room temperature. After blocking, the membranes were incubated in specific antibody solutions (Rabbit monoclonal anti-AchE, 1:1000, Abcam-ab183591, USA; Rabbit monoclonal anti-PSD95, 1:3000, Abcam-ab76115, USA; Rabbit monoclonal anti-BDNF, 1:5000, Abcam-ab108319, USA; Rabbit polyclonal anti-β-actin, 1:10000, Proteintech-20536-1-AP, China) overnight at 4°C, followed by 1×TBS-T washing steps and then incubation with biotinylated antibody solutions (Proteintech, China) for 1 h. Blots were washed again and were placed into chemiluminescent HRP substrate (Millipore, USA) for 2 mins followed by observed by Clinxchemi Scope 6000 (Clinx, China). The absorbance values of the bands were quantified using an image analysis system and Image J. The protein levels were normalized against the β-actin intensity.

2.8. HE staining {#sec010}
----------------

Hematoxylin-eosin (HE) staining was performed on paraffin sections of brain tissue. Anesthetized rats were perfused with saline followed by 4% paraformaldehyde solution. The brains were then collected and immersed in 4% paraformaldehyde. After dehydration and vitrification, the brains were embedded in paraffin and cut into 6-μm sections from Bregma -2.16 mm to -4.20 mm. Serial sections (every 10th; intervals of 60-μm) were adhered to glass slides precoated with polyethylenimine. Paraffin-embedded brain sections were dewaxed with xylene and rehydrated with an ethanol series (absolute, 95%, 90%, 80%). The sections were then stained with HE, and images shown were acquired with Automatic digital slice scanning system (KFBio, China).

2.9. Morris water maze test {#sec011}
---------------------------

Four weeks after HIBD, 30-day-old rats were subjected to the Morris water maze test as described previously \[[@pone.0228825.ref022]\]. In brief, an open circular water-filled pool with a diameter of 160 cm, a height of 50 cm and a temperature of 22±1°C was prepared. The pool was divided into four quadrants, each of which had a reference object consisting of a different colored shape. In the experiment, animals were trained with no platform sessions to experience the pool environment (Day 0), and then hidden platform sessions were performed four times a day at 30-min intervals (Days 1--4). The platform was in the center of the NE quadrant and was placed 1.5\~2 cm below the surface of the water during the hidden tests. Each trial had a limit of 60 sec, and the time to find the platform (escape latency) was recorded. At Day 5, after removing the platform, the probe test was conducted in which the time spent in each quadrant during 60 sec and the swimming route were recorded. The swimming behavior of the rats was recorded and tracked by an overhead video camera connected to a PC with an automated tracking software, and the data were analyzed using the behavior analysis system (Shanghai Xinruan Information Technology Co., Ltd., Shanghai, China).

2.10. Statistical analyses {#sec012}
--------------------------

All data are expressed as the means ± standard error (SE). Statistical analyses and statistical graph were performed using GraphPad Prism 7 software. Differences between two groups were evaluated statistically by using unpaired Student's t test. Differences among three or more groups were compared by analysis of variance (ANOVA) which with Tukey's adjustment for multiple comparisons. *P*\<0.05 was considered statistically significant.

3. Result {#sec013}
=========

3.1. FA ameliorated cerebral palsy, memory impairment and learning disabilities in HIBD rats {#sec014}
--------------------------------------------------------------------------------------------

To determine whether FA can rescue HIBD-induced cerebral palsy, memory impairment and learning disabilities in neonatal rats, HE staining and the Morris water maze test were conducted.

Coronal section of the cerebral cortex and hippocampus showed that the area of the cerebral cortex, the size of the hippocampus and the layers of the dentate gyrus (DG) were dramatically decreased in the HIBD group compared with the sham group, and the administration of FA significantly suppressed the decrease in hippocampal neurons, the area of cerebral cortex, the size of the hippocampus and the layers of the DG ([Fig 1A--1C](#pone.0228825.g001){ref-type="fig"}, *P* \< 0.001 vs. HIBD).

![FA ameliorated brain tissue loss in HIBD rats.\
(A) Coronal sections stained with hematoxylin-eosin are shown. (B, C) Quantification of the size of the hippocampus and the layers of the hippocampal dentate gyrus in the different groups. *\*\*\*\* P* \< 0.0001, *\*\*\* P* \< 0.001. N = 6 for HE staining.](pone.0228825.g001){#pone.0228825.g001}

To evaluate long-term spatial learning and memory ability, the Morris water maze was performed on 35-day-old rats after SF application. In the acquisition trial, HIBD rats showed decreased spatial learning ability with a significantly increased escape latency compared with those of the control and sham groups on the training days. Importantly, as shown in [Fig 2A](#pone.0228825.g002){ref-type="fig"}, daily SF treatment significantly ameliorated the impairment induced by HIBD (*P* \<0.001). In the retention trial, a significant reduction in the exploration distance in the target quadrant was observed in HIBD rats compared with HIBD+SF rats ([Fig 2B and 2C](#pone.0228825.g002){ref-type="fig"}, *P* \< 0.001). These results further confirmed that spatial memory retrieval was impaired after HIBD and that FA treatment succeeded in preventing this impairment.

![FA ameliorated learning and memory impairments in HIBD rats.\
(A) The escape latency (T value) of the rats in the training period. (B) The exploration distance (P value) of the rats in the exploratory trials. (C) The exploration route in the retention trial. *\*\*\*\* P* \< 0.0001, *\*\*\* P* \< 0.001. N = 10 for Morris water maze analysis.](pone.0228825.g002){#pone.0228825.g002}

Taken together, these results indicate that FA treatment alleviates deficits in ischemia-induced cell death and learning and memory function in neonatal rats after HIBD.

3.2. The expression of miR-9 significantly increased under hypoxic-ischemic conditions, and FA attenuated the expression of miR-9 {#sec015}
---------------------------------------------------------------------------------------------------------------------------------

To establish whether miR-9 is involved in HIBD, we investigated the expression levels of miR-9 in the PC12 cells and hippocampus of HI condition compared with control using RT-PCR analysis. The RT-PCR results showed that the expression level of miR-9 in PC12 cells was markedly higher after HI injury than in the control groups ([Fig 3A](#pone.0228825.g003){ref-type="fig"}, *P* \<0.05). Similarly, miR-9 expression was almost doubled in the hippocampus of hypoxic-ischemic rats compared to sham rats ([Fig 3B](#pone.0228825.g003){ref-type="fig"}, *P* \<0.01). To further determine the therapeutic effects of FA on HIBD, we examined the expression levels of miR-9 after treating the rats with SF daily for 5 days and then compared them with the levels in the sham group. In PC12 cells cultured under serum-oxygen deprivation conditions for 2 h, miR-9 release was significantly reduced after treatment with SF ([Fig 3C](#pone.0228825.g003){ref-type="fig"}, *P* \<0.05). Similar results were also observed in HIBD rats, and the expression levels of miR-9 were markedly lower in the HIBD+SF group than in the HIBD group ([Fig 3D](#pone.0228825.g003){ref-type="fig"}, *P* \<0.01). These results further confirmed that miR-9 plays an important role in neonatal HIBD and that the neuroprotective effect of FA may occur through the downregulation of the expression levels of miR-9.

![FA attenuated the upregulation of miR-9 under hypoxic-ischemic conditions in cultured PC12 cells and the rat hippocampus.\
(A) RT-PCR analysis of miR-9 expression in PC12 cells after HI. (B) RT-PCR analysis of miR-9 expression in the rat hippocampus after HIBD. *\*\* P* \< 0.01, *\* P* \< 0.05 vs. control. (C) RT-PCR analysis of miR-9 expression in PC12 cells after FA treatment. (D) RT-PCR analysis of miR-9 expression in the rat hippocampus after FA treatment. *\*\* P* \< 0.01, *\* P* \< 0.05 vs. HIBD. N = 4 for cell analysis and N = 6 for animal analysis.](pone.0228825.g003){#pone.0228825.g003}

3.3. Inhibition of miR-9 protected against hypoxic-ischemic brain damage in neonatal rats {#sec016}
-----------------------------------------------------------------------------------------

To further reveal the role of miR-9 following hypoxic-ischemic damage. We investigated whether inhibiting the expression of miR-9 in vivo protects hippocampal neurons. We injected LNA-miR-9 (400 μM) into the lateral ventricle of 21-day-old neonatal rats after HIBD. LNA-miR-9 treatment significantly reduced brain injury in the rats, which resulted in a significant increase in the surviving brain volume and cell layers of the DG compared to that of the HIBD+PBS group ([Fig 4A--4C](#pone.0228825.g004){ref-type="fig"}, *P* \<0.001). The Morris water maze was performed on 35-day-old rats after LNA-miR-9 application.

![LNA-miR-9 attenuated brain tissue loss in HIBD rats.\
(A) Coronal sections stained with hematoxylin/eosin are shown. (B, C) Quantification of the size of the hippocampus and the layers of hippocampal dentate gyrus in the different groups. *\*\*\* P* \< 0.001 vs HIBD+PBS. N = 6 for HE staining.](pone.0228825.g004){#pone.0228825.g004}

In the acquisition trial, HIBD+PBS rats showed decreased spatial learning ability with a significantly increased escape latency. Notably, LNA-miR-9 treatment significantly ameliorated the impairments of HIBD+PBS rats ([Fig 5A](#pone.0228825.g005){ref-type="fig"}, *P* \< 0.001). In the retention trial, a significant reduction in the exploration distance in the target quadrant was observed in HIBD+PBS rats compared with HIBD+LNA rats ([Fig 5B and 5C](#pone.0228825.g005){ref-type="fig"}, *P* \< 0.001). These results indicated that LNA-miR-9 protected against brain injury induced by HIBD in rats.

![LNA-miR-9 attenuated learning and memory impairments in HIBD rats.\
(A) The escape latency (T value) of the rats in the training period. (B) The exploration distance (P value) of the rats in the exploratory trials. (C) The exploration route in the retention trial. \*\*\* *P* \< 0.001 vs HIBD+PBS. N = 10 for Morris water maze analysis.](pone.0228825.g005){#pone.0228825.g005}

3.4. FA and LNA-miR-9 protected against synaptic marker loss induced by HI {#sec017}
--------------------------------------------------------------------------

AchE is a polymorphic enzyme commonly known for its cholinergic action that stops cholinergic signaling in the brain by hydrolyzing acetylcholine to choline and acetate \[[@pone.0228825.ref023]\]. The expression of AchE is closely correlated with the neuroinflammatory response and neurological dysfunction \[[@pone.0228825.ref024], [@pone.0228825.ref025]\]. Studies have shown that the expression of AchE is increased after hypoxia-ischemia (HI) in newborn rats. Further research has confirmed that the inhibition of the AchE receptor reduces brain damage after HI \[[@pone.0228825.ref026]\]. Previous reports have indicated that postsynaptic density protein (PSD)-95 expression is markedly decreased in the hippocampal CA1 region after brain injury \[[@pone.0228825.ref027]--[@pone.0228825.ref029]\]. Therefore, we currently investigated neuroprotective effect of FA on HIBD in rats by examining the expression of AchE and PSD-95.

As shown in [Fig 6A and 6B](#pone.0228825.g006){ref-type="fig"}, the expression of AchE mRNA in the PC12 cells and rat hippocampus was significantly higher in the HI group and HIBD group (*P \<*0.01 vs HI and *P \<*0.05 vs HIBD). SF and LNA-miR-9 notably decreased the HI-induced upregulation of AchE mRNA (*P \<*0.01 vs HI, *P \<*0.05 vs HIBD and *P \<*0.01 vs HIBD+PBS). On the other hand, hypoxia-ischemia significantly reduced the expression of PSD-95 mRNA in the PC12 cells and rat hippocampus (*P \<*0.05 vs Con and Sham). After SF and LNA-miR-9 treatment, the expression of PSD-95 mRNA increased ([Fig 6C and 6D](#pone.0228825.g006){ref-type="fig"}, *P \<*0.01 vs HI, *P \<*0.05 vs HIBD and HIBD+PBS).

![RT-PCR analysis of the gene expression of AchE mRNA and PSD-95 mRNA in PC12 cells and rat hippocampus.\
SF and LNA effectively reversed the expression changes in AchE mRNA and PSD-95 mRNA caused by hypoxic-ischemic injury. (A) The expression of AchE mRNA in PC12 cells. (B) The expression of AchE mRNA in the rat hippocampus. (C) The expression of PSD-95 mRNA in PC12 cells. (D) The expression of PSD-95 mRNA in the rat hippocampus. \*\* *P* \< 0.01, \* *P* \< 0.05. N = 4 for cell analysis and N = 6 for animal analysis.](pone.0228825.g006){#pone.0228825.g006}

In addition, Western blot analysis was performed to verify the protein expression levels of AchE and PSD-95 in the PC12 cells and rat hippocampus. The results shown in [Fig 7A](#pone.0228825.g007){ref-type="fig"}, [7B](#pone.0228825.g007){ref-type="fig"}, [7C and 7D](#pone.0228825.g007){ref-type="fig"} suggest that hypoxia-ischemia significantly increased the protein levels of AchE and decreased the levels of PSD-95 compared with those in the control group and sham group (*P \<*0.01). Meanwhile, treatment with SF and LNA-miR-9 reduced the protein levels of AchE and upregulated the protein expression of PSD-95 (*P \<*0.01 vs HI, *P* \<0.01 vs HIBD and HIBD+PBS). Collectively, these results indicated that miR-9 mediated the neuroprotective effect of FA against HIBD.

![Western blot analysis of the protein expression of AchE and PSD-95 in PC12 cells and rat hippocampus.\
SF and LNA-miR-9 effectively reversed the expression changes in AchE and PSD-95 caused by ischemic-hypoxic injury. (A) The expression of AchE in PC12 cells. (B) The expression of AchE in the rat hippocampus. (C) The expression of PSD-95 in PC12 cells. (D) The expression of PSD-95 in the rat hippocampus. \*\*\* *P* \< 0.001, \*\* *P* \< 0.01 vs HIBD or HIBD+PBS. N = 4 for cell analysis and N = 6 for animal analysis.](pone.0228825.g007){#pone.0228825.g007}

3.5. BDNF signaling participated in the neuroprotective effects of FA in HIBD neonatal rats {#sec018}
-------------------------------------------------------------------------------------------

Brain-derived neurotrophic factor (BDNF) has been recognized as a protective effector of synaptic transmission and cognitive function after HI brain injury \[[@pone.0228825.ref030]\]. Previous reports have shown that the expression levels of BDNF are directly regulated by miRs and that miR-9 plays an important role in the regulation of axonal projections in response to BDNF signaling \[[@pone.0228825.ref031]\]. Therefore, we examined whether BDNF signaling functions in mediating miR-9 expression in HIBD neonatal rats. Western blot analysis revealed that BDNF expression was significantly decreased in the hippocampus of the rats in the HIBD group compared with those in the sham group after hypoxic-ischemic damage (*P* \<0.01). In the neonatal rats in the HIBD+SF and HIBD+LNA-miR-9 groups, increased BDNF protein expression was observed ([Fig 8A](#pone.0228825.g008){ref-type="fig"}, *P* \<0.01 vs HIBD and HIBD+PBS). These results confirmed that FA regulated miR-9 expression by increasing the release of BDNF.

![Western blot analysis of the protein expression of BDNF in the rat hippocampus.\
SF and LNA-miR-9 effectively increased the expression of BDNF in HIBD. (A) The expression of BDNF in rat hippocampus. \*\* *P* \< 0.01 vs HIBD or HIBD+PBS. N = 6 for animal analysis.](pone.0228825.g008){#pone.0228825.g008}

Discussion {#sec019}
==========

HIBD is one of the major causes of neonatal death and disability in human neonates worldwide \[[@pone.0228825.ref032]\]. It is urgent to identify drugs that protect against neuronal damage to reduce the neurological disorder induced by HIBD. In this study, we demonstrated for the first time that FA can improve learning and memory impairment caused by HIBD in rats. The neuroprotective effects of FA are likely the result of the regulation of miR-9 expression through increased release of BDNF. We established HIBD model used on P7 rats, because P7 rats correspond to human neonatal \[[@pone.0228825.ref033]\]. However, it is difficult to inject LNA-miR-9 with a stereotaxic instrument on the P7 damaged brain. P21 rats are in the stage of high-speed brain growth and development, and drug intervention at this stage can observe the effect of FA and LNA-miR-9 on the neurological sequelae effectively.

A growing number of researchers have discovered the beneficial influence of FA in stress-induced injury \[[@pone.0228825.ref034]\]. Treatment with FA has a protective effect by reducing oxidative stress and inhibiting ROS production in PC12 cells treated with the neurotoxin lead acetate \[[@pone.0228825.ref035]\]. Consistently, a previous report also revealed that FA possesses the ability to inhibit LPS-induced neuroinflammation \[[@pone.0228825.ref036]\]. However, little is known about its protective effects in HI brain injury. Previous reports have indicated that hypoxia-ischemia can reduce the long-term spatial learning and memory ability of rats \[[@pone.0228825.ref037]\]. Our results showed that the size and neurons number of cerebral cortex and hippocampus were increased compared with those of the HIBD group and the HIBD+PBS group after treatment with SF and LNA-miR-9 by HE staining, indicated that FA can relieve the damage of brain significantly. Behavioral experiments showed that after treatment with SF and LNA-miR-9, the T value was significantly shortened and the P value was significantly prolonged compared with those of the HIBD group and HIBD+PBS group, suggesting that FA can improve the spatial learning and memory ability of HIBD rats.

MicroRNAs are small, noncoding RNAs that negatively regulate the expression of target mRNAs through degradation and translational inhibition \[[@pone.0228825.ref038]\]. An increasing number of studies have shown that microRNAs play an important regulatory role in neurodevelopment, metabolism and cancer \[[@pone.0228825.ref039]--[@pone.0228825.ref041]\]. miR-9 is a highly expressed miRNA in the brain and is enriched in synapses. Studies have shown that miR-9 can promote proliferation, migration, differentiation and apoptosis and regulate the dendrites of neurons \[[@pone.0228825.ref042]--[@pone.0228825.ref045]\]. However, whether miR-9 is involved in hypoxic-ischemic injury and recovery in the rat brain has not been clearly reported. This study found that the expression of miR-9 in PC12 cells and the hippocampus of the rats in the model group was significantly upregulated compared with that in the normal group, indicating that ischemia-hypoxia can influence the level of miR-9 expression in the process of neuronal damage. In addition, after SF treatment, the expression of miR-9 was significantly lower, revealing that FA improve the learning and memory ability of HIBD rats by downregulating the expression of miR-9.

BDNF is broadly expressed in the developing mammalian brain, and evidence has shown that hypoxia-ischemia in rats results in increased BDNF expression in neurons \[[@pone.0228825.ref046]\]. Our experiments found that BDNF expression was significantly increased after treatment with FA and the inhibition of the expression levels of miR-9 in HIBD. In addition, the inhibition of miR-9 can downregulate the expression of AchE and upregulate the expression of PSD-95. The mechanism may be that the increased release of BDNF can protect against neuronal death in the rat hippocampus. This ensures the normal transmission of neuronal signals, thus effectively inhibiting nerve damage after hypoxia. In addition, there may be other mechanisms by which FA improves the learning and memory ability of rats with hypoxic-ischemic injury. Further research is needed to clarify the mechanism underlying the effect of FA in the treatment of HIBD and make better use of it in the clinic; traditional Chinese medicine containing FA provides a theoretical basis for the treatment of HIBD.
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When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. As part of your revision, please complete and submit a copy of the ARRIVE Guidelines checklist, a document that aims to improve experimental reporting and reproducibility of animal studies for purposes of post-publication data analysis and reproducibility: <https://www.nc3rs.org.uk/arrive-guidelines>. Please include your completed checklist as a Supporting Information file. Note that if your paper is accepted for publication, this checklist will be published as part of your article. As part of your revisions please be sure to specify the number of animals used in your study, including details of any animals that were excluded from your study for any reason (including death).

3\. Please include in Methods section the source of the cell lines.

4\. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission's figures or Supporting Information files. This policy and the journal's other requirements for blot/gel reporting and figure preparation are described in detail at <https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements> and <https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files>. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: <https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels>.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at <plosone@plos.org> if you have any questions.

5\. We note you have included a table to which you do not refer in the text of your manuscript. Please ensure that you refer to Table 1 in your text; if accepted, production will need this reference to link the reader to the Table.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The paper authored by Keli Yao, and colleagues investigates the neuroprotective effects of Ferulic acid (FA) on learning and memory improvement in rats subjected to neonatal hypoxic-ischemic brain damage (NHIBD). They hypothesized that neuroprotective effects of FA are likely the result of the regulation of miR-9 expression through increased release of BDNF. In particular, researchers demonstrated that the intraperitoneally administration of Sodium ferulic (50 mg/kg) into the rats starting from to postnatal day twenty-one, one time per day for 5 days, induced the reduction hippocampal damage and prevented impairment in spatial learning and memory ability, evaluated by using Morris water maze test. In addition, they showed that the expression levels of miR-9 was significantly increased in the hippocampus of hypoxic-ischemic rats compared to sham rats. Moreover, they demonstrated that there was a significant reduction of the expression levels of miR-9 after treating the rats with SF daily for 5 days and then compared them with the levels in the sham group. In the same way, in vitro model, they observed in PC12 cells cultured under serum-oxygen deprivation conditions for 2 hours, that miR-9 release was significantly reduced after treatment with SF. Furthermore, they showed that the inhibition of miR-9, by using of LNA-miR-9, protected the hippocampus and ameliorated the spatial learning ability of rats subjected to NHIBD. They also observed, in the rat hippocampus and PC12 cells, that the treatment with SF and LNA-miR-9 determined the reduction of expression levels of AchE mRNA and protein, and induced the increase of expression levels of PSD-95 mRNA and protein. In the last part of work, the authors demonstrated that expression levels of BDNF protein significantly decreased in the hippocampus of the rats in HIBD group compared with those in the sham group after hypoxic-ischemic damage, conversely, in HIBD+SF and HIBD+LNA-miR-9 groups, increased BDNF protein expression had been observed.

Although the manuscript technically sounds, experiments have been performed with rigor, through appropriate controls, replication and sample size and the data produced support the conclusions, some points should be improved to reinforce the significance of the paper.

1\. In the "discussion" section, it is necessary to explain, why they choose the dose of Sodium ferulic (50 mg/kg) for the intraperitoneally administration into the rats, since the mentioned papers used different dosage protocols.

2\. In the "discussion" section, it is necessary to explain why they choose to start FA 21 days postnatally. It would be appropriate to understand whether the administration of FA starting from the phases immediately subsequent the induction of the damage, may also determine a greater neuroprotective effect in animals.

3\. Authors should show the effect of FA administration in the cortex, since cortex is one of the main damaged areas after an hypoxic-ischemic damage.

4\. In "methods" section, it is appropriate to indicate the total number of rats were used in the paper.

5\. In "methods" section, it is appropriate to indicate the total number of slices for each mouse used to perform the H-E staining, also reporting the bregma coordinate.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0228825.r002
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Reviewer \#1:

1\. Response to comment: Why we choose the dose of Sodium ferulic (50 mg/kg) for the intraperitoneally administration into the rats.

Response: The dose of Sodium ferulic (50 mg/kg) is calculated by the Animal equivalent dose calculation based on body surface area. The calculation procedure is:

AED (mg / kg) = Human does (mg / kg) × Km ratio = 8.1 (mg / kg) × (37/6) = 50 mg / kg in rats. We have supplemented these data in the "methods and materials" section.

2\. Response to comment: Why we choose to start FA at P21 rats.

Response: Since it is difficult to inject LNA-miR-9 with a stereotaxic instrument on the P7 damaged brain. 21-day-old rats are in the stage of high-speed brain growth and development, and drug intervention at this stage can observe the effect of FA and LNA-miR-9 on the neurological sequelae effectively. In addition, intraperitoneal injection of SF and brain stereotactic injection of LNA-miR-9 need to be synchronized at the same time, and the surgery of brain stereotactic injection is an invasive craniotomy, considering that rats are weaned at 21 days postnatally and have ability to eat independently, thus we choose to start drug treatment at P21 rats.

3\. Response to comment: About "Authors should show the effect of FA administration in the cortex".

Response: HE staining showed changes in the rat cerebral cortex and hippocampus, but the changes in the cerebral cortex were far less than those of in the rat hippocampus. Furthermore, since we mainly studied learning and memory impairment caused by HIBD, which is closely related to the hippocampus, the results of the cerebral cortex changes are only shown by HE staining. Relevant content about cerebral cortex have been supplemented in the paper.

4\. Response to comment: About "indicate the total number of rats were used in the paper".

Response: In this experiment, we used 168 rats, which have been supplemented in the "methods and materials" section.

5\. Response to comment: About "indicate the total number of slices for each mouse used to perform the H-E staining, also reporting the bregma coordinate".

Response: In this experiment, the brains were cut into 6-μm sections from Bregma -2.16 mm to -4.20 mm. Series of each 10 consecutive sections (intervals of 60μm) were cut and stained with HE.

Other changes: In the "Introduction" section and the "methods and materials" section, several statements that we made were more ambiguous than intended, and we have adjusted to the text to be clearer. We tried our best to improve the manuscript and made some changes in the manuscript. These changes will not influence the content and framework of the paper. And here we did not list the changes but marked in red in revised paper.

###### 

Submitted filename: Response to Reviewers.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0228825.r003
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Dear Dr. Yao,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Giuseppe Pignataro, MD, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The manuscript technically sounds, experiments have been performed with rigor, through appropriate controls, replication and sample size and the data produced support the conclusions.

The authors answered to comments and made the necessary changes to improve the manuscript.

I accepted the revision of the paper by Keli Yao and colleagues.

However, I would like to precise that, although the paper has been generally improved and is now suitable for publication, it is necessary to introduce these modifies before accepting it for publication:

1\) In the revised paper, in the "introduction" section, in the sentence "In conclusion, we aimed to explore neuroprotective effect of FA on HIBD patients and ..." (this sentence have been highlighted by authors by using red text to indicate the changes made). It is necessary that the authors correct the word "patients" with rats, because the study has been performed in rats and not in patients.

2\) In the revised paper, in the "methods" section, in the sentence "The rats were divided into six groups randomly and treated in the following cohorts: In HIBD group, HIBD+SF group, HIBD+LNA group and HIBD+PBS group, the HIBD model was established by the classic method of Rice-Vannucci (this sentence have been highlighted by authors by using red text to indicate the changes made). It is necessary that the authors, indicate that it has been performed a few modification, because they reported in the next sentence that: "The left carotid artery of 7-day-old SD rats was permanently unilateral

ligated and removed,..."(this sentence was already present in the first version of paper).

3\) In the revised paper, in the "methods" section, It is necessary that the authors, indicate the gender of rats used in the procedure.

4\) In the revised paper, in the "discussion" section, in the sentence "We established HIBD model used on P7 rats, because P7 rats correspond to human neonatal" (this sentence have been highlighted by authors by using red text to indicate the changes made). It is necessary that the authors improve the second part of this affirmation and add a reference.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No
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Acceptance letter

Pignataro

Giuseppe

Academic Editor

© 2020 Giuseppe Pignataro

2020

Giuseppe Pignataro

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

20 May 2020

PONE-D-20-01760R1

MicroRNA-9 Mediated the Protective Effect of Ferulic Acid on Hypoxic-Ischemic Brain Damage in Neonatal Rats

Dear Dr. Yao:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Giuseppe Pignataro

Academic Editor

PLOS ONE
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